AtriCure Reports Second Quarter 2015 Financial Results and Updates 2015 Outlook
- Revenue of $32.6 million – up 22.9% as reported, 26.5% constant currency
- U.S. sales of $25.7 million – up 29.3%
- International sales of $6.8 million – up 3.5% as reported, 17.9% constant currency
WEST CHESTER, Ohio--- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in technologies for the surgical treatment of atrial fibrillation and left atrial appendage management, today announced second quarter 2015 financial results.
“We are pleased by our results this quarter which reflect continued stability in our business and the solid foundation AtriCure is building for future growth,” said Mike Carrel, President and Chief Executive Officer of AtriCure. “With our long term investments in clinical trials, innovation, and physician training and education, we look forward to continuing to advance the treatment of atrial fibrillation.”
- Published: 29 July 2015
- Written by Editor